Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD5 CAR Engineered IL15-Transduced CB-NK Cells for Relapsed/Refractory Hematological Malignancies
NCT05110742Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2024
- Primary completion
- Dec 2030
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of iC9/CD5CAR/IL-15 NK cells in hematological malignancy, T-cell lymphoma, t-cell acute lymphoblastic leukemia (T-ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2024; status: recruiting.
02
Drugs
iC9/CD5CAR/IL-15 NK cells
03
Conditions
hematological malignancyT-cell lymphomat-cell acute lymphoblastic leukemia (T-ALL)chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05110742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110742.